disease_type	disease_id	cell_type	celltype_species	cell_ID	cell_def	marker	marker_type	database_specificity	EC_score	species	gene_description	database
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	ADGRE5	positive	1.00	1	Human	adhesion G protein-coupled receptor E5 	de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell 34, 674–689.e8 (2018).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	ADGRG1	positive	0.25	4	Human	adhesion G protein-coupled receptor G1 	Daga S., Rosenberger A., Quehenberger F., Krisper N., Prietl B., Reinisch A., Zebisch A., Sill H., Wolfler A. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML. Cancer Med. 2019;8:1771–1778. doi: 10.1002/cam4.2053.; Pabst C., Bergeron A., Lavallée V.P., Yeh J., Gendron P., Norddahl G.L., Krosl J., Boivin I., Deneault E., Simard J., et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016;127:2018–2027. doi: 10.1182/blood-2015-11-683649.; Huang K.Y., Lin H.H. The activation and signaling mechanisms of GPR56/ADGRG1 in melanoma cell. Front. Oncol. 2018;8:304. doi: 10.3389/fonc.2018.00304.; Solaimani Kartalaei P., Yamada-Inagawa T., Vink C.S., de Pater E., van der Linden R., Marks-Bluth J., van der Sloot A., van den Hout M., Yokomizo T., van Schaick-Solerno M.L., et al. Whole-transcriptome analysis of endothelial to hematopoietic stem cell transition reveals a requirement for Gpr56 in HSC generation. J. Exp. Med. 2015;212:93–106. doi: 10.1084/jem.20140767.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	BMI1	positive	1.00	1	Human	BMI1 proto-oncogene, polycomb ring finger 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	BST1	negative	1.00	1	Human	bone marrow stromal cell antigen 1 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	BST2	positive	1.00	1	Human	bone marrow stromal cell antigen 2 	ThermoFisher
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	BACH2	positive	0.50	2	Human	BTB domain and CNC homolog 2 	Herviou, L., Kassambara, A., Boireau, S. et al. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenet10, 121 (2018). https://doi.org/10.1186/s13148-018-0554-4; Muto A, Ochiai K, Kimura Y, Itoh-Nakadai A, Calame KL, Ikebe D, Tashiro S, Igarashi K. Bach2 represses plasma cell gene regulatory network in B cells to promote antibody class switch. EMBO J. 2010 Dec 1;29(23):4048-61. doi: 10.1038/emboj.2010.257. Epub 2010 Oct 15. PMID: 20953163; PMCID: PMC3020649.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CCL1	positive	1.00	1	Human	C-C motif chemokine ligand 1 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CLEC12A	positive	0.08	1	Human	C-type lectin domain family 12 member A 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CLEC12A	positive	0.08	3	Human	C-type lectin domain family 12 member A 	Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; van Rhenen, A. et al. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood110, 2659–2666 (2007).; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CLEC12A	positive	0.08	8	Human	C-type lectin domain family 12 member A 	Marshall A.S.J., Willment J.A., Pyz E., Dennehy K.M., Reid D.M., Dri P., Gordon S., Wong S.Y.C., Brown G.D. Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur. J. Immunol. 2006;36:2159–2169. doi: 10.1002/eji.200535628.; van Rhenen, A. et al. The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood110, 2659–2666 (2007).; Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Bakker, A.B.; van den Oudenrijn, S.; Bakker, A.Q.; Feller, N.; van Meijer, M.; Bia, J.A.; Jongeneelen, M.A.; Visser, T.J.; Bijl, N.; Geuijen, C.A.; et al. C-type lectin-like molecule-1: A novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res. 2004, 64, 8443–8450.; Jiang, Y.P.; Liu, B.Y.; Zheng, Q.; Panuganti, S.; Chen, R.; Zhu, J.; Mishra, M.; Huang, J.; Dao-Pick, T.; Roy, S.; et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018, 2, 1738–1749; Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Daga, S.; Rosenberger, A.; Quehenberger, F.; Krisper, N.; Prietl, B.; Reinisch, A.; Zebisch, A.; Sill, H.; Wolfler, A High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML. Cancer Med. 2019, 8, 1771–1778.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CXCR4	positive	1.00	1	Human	C-X-C motif chemokine receptor 4 	Gwendolin Muehlinghaus, Luisa Cigliano, Stephan Huehn, Anette Peddinghaus, Heike Leyendeckers, Anja E. Hauser, Falk Hiepe, Andreas Radbruch, Sergio Arce, Rudolf A. Manz; Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005; 105 (10): 3965–3971. doi: https://doi.org/10.1182/blood-2004-08-2992
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CDH2	positive	1.00	1	Human	cadherin 2 	CellMarker
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	CD19	positive	0.11	1	Human	CD19 molecule 	Bagheri, M., Vosoughi, T., Hosseinzadeh, M. et al. Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes13, 412 (2020). https://doi.org/10.1186/s13104-020-05243-7
B-cell acute lymphoblastic leukemia	DOID:0080638	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:0080638-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD19	positive	0.11	1	Human	CD19 molecule 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD19	positive	0.11	1	Human	CD19 molecule 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD19	positive	0.11	2	Human	CD19 molecule 	CellMarker; Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1. PMID: 27479184; PMCID: PMC5439510.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD19	negative	0.11	4	Human	CD19 molecule 	Solimando, A.G.; Da Vià, M.C.; Bolli, N.; Steinbrunn, T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. Cancers 2022, 14, 3271. https://doi.org/10.3390/cancers14133271; BioCompare; Milteny Biotec; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD2	positive	1.00	1	Human	CD2 molecule 	van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520–7.
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	CD200	positive	0.20	1	Human	CD200 molecule 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD200	positive	0.20	2	Human	CD200 molecule 	Ngwa C., Liu F. CD200-CD200R signaling and diseases: A potential therapeutic target? Int. J. Physiol. Pathophysiol. Pharmcol. 2019;11:297–309.; Ho J.M., Dobson S.M., Voisin V., McLeod J., Kennedy J.A., Mitchell A., Jin L., Eppert K., Bader G., Minden M.D., et al. CD200 expression marks leukemia stem cells in human AML. Blood Adv. 2020;4:5402–5413. doi: 10.1182/bloodadvances.2020001802.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD200	positive	0.20	2	Human	CD200 molecule 	Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; BioCompare
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD22	positive	1.00	1	Human	CD22 molecule 	Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD244	positive	0.25	4	Human	CD244 molecule 	Haubner S., Perna F., Köhnke T., Schmidt C., Berman S., Augsberger C., Schnorfeil F.M., Krupka C., Lichtenegger F.S., Liu X., et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64–74. doi: 10.1038/s41375-018-0180-3.; Zhang F., Liu X., Chen C., Zhu J., Yu Z., Xie J., Xie L., Bai H., Zhang Y., Fang X., et al. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling. Haematologica. 2017;102:707–718. doi: 10.3324/haematol.2016.151555.; Agresta L., Hoebe K.H.N., Janssen E.M. The emerging role of CD244 signaling in immune cells of the tumor microenvironment. Front. Immunol. 2018;9:2809. doi: 10.3389/fimmu.2018.02809.; Quek L., Otto G.W., Garnett C., Lhermitte L., Karamitros D., Stoilova B., Lau I.J., Doondeea J., Usukhbayar B., Kennedy A., et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J. Exp. Med. 2016;213:1513–1535. doi: 10.1084/jem.20151775.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD27	positive	0.14	1	Human	CD27 molecule 	Riether C., Schürch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187–198. doi: 10.1038/cdd.2014.89.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD27	positive	0.14	1	Human	CD27 molecule 	Riether C., Schürch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187–198. doi: 10.1038/cdd.2014.89.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD27	negative	0.14	5	Human	CD27 molecule 	BioCompare; Milteny Biotec; Bin Chu, Li Bao, Yutong Wang, Minqiu Lu, Lei Shi, Shan Gao, Lijuan Fang, Qiuqing Xiang, Xi Liu,CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma, Clinical Immunology,Volume 213,2020,108363,ISSN 1521-6616,https://doi.org/10.1016/j.clim.2020.108363.; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; Solimando, A.G.; Da Vià, M.C.; Bolli, N.; Steinbrunn, T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. Cancers 2022, 14, 3271. https://doi.org/10.3390/cancers14133271
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD28	positive	0.33	3	Human	CD28 molecule 	Milteny Biotec; BioCompare; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD33	positive	0.08	2	Human	CD33 molecule 	Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; BioCompare
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD33	positive	0.08	3	Human	CD33 molecule 	Jilani, I. et al. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol.118, 560–566 (2002).; Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD33	positive	0.08	7	Human	CD33 molecule 	Haubner S., Perna F., Köhnke T., Schmidt C., Berman S., Augsberger C., Schnorfeil F.M., Krupka C., Lichtenegger F.S., Liu X., et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64–74. doi: 10.1038/s41375-018-0180-3.; Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Jilani, I. et al. Differences in CD33 intensity between various myeloid neoplasms. Am. J. Clin. Pathol.118, 560–566 (2002).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ehninger A., Kramer M., Röllig C., Thiede C., Bornhäuser M., von Bonin M., Wermke M., Feldmann A., Bachmann M., Ehninger G., et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218. doi: 10.1038/bcj.2014.39.; Laszlo G.S., Estey E.H., Walter R.B. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143–153. doi: 10.1016/j.blre.2014.04.001.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	Cd34	positive	1.00	1	Mouse	CD34 antigen 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD34	positive	0.10	1	Human	CD34 molecule 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD34	positive	0.10	1	Human	CD34 molecule 	Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
acute lymphoblastic leukemia	DOID:9952	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9952-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD34	positive	0.10	1	Human	CD34 molecule 	Nielsen J.S., McNagny K.M. Erratum: Novel functions of the CD34 family. J. Cell Sci. 2008;121:3683–3692. doi: 10.1242/jcs.037507.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD34	positive	0.10	7	Human	CD34 molecule 	Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014 Sep 22;9(9):e107587. doi: 10.1371/journal.pone.0107587. PMID: 25244440; PMCID: PMC4171508.; CellMarker; Hwang K, Park CJ, Jang S, Chi HS, Kim DY, Lee JH, Lee JH, Lee KH, Im HJ, Seo JJ. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol. 2012 Oct;91(10):1541-6. doi: 10.1007/s00277-012-1501-7. Epub 2012 Jun 6. PMID: 22669506.; Nielsen J.S., McNagny K.M. Erratum: Novel functions of the CD34 family. J. Cell Sci. 2008;121:3683–3692. doi: 10.1242/jcs.037507.; Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Hanekamp, D., Cloos, J. & Schuurhuis, G.J. Leukemic stem cells: identification and clinical application. Int J Hematol 105, 549–557 (2017). https://doi.org/10.1007/s12185-017-2221-5; Quek L., Otto G.W., Garnett C., Lhermitte L., Karamitros D., Stoilova B., Lau I.J., Doondeea J., Usukhbayar B., Kennedy A., et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J. Exp. Med. 2016;213:1513–1535. doi: 10.1084/jem.20151775.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD36	positive	0.50	1	Human	CD36 molecule 	Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD36	positive	0.50	1	Human	CD36 molecule 	Sachs K., Sarver A.L., Noble-Orcutt K.E., LaRue R.S., Antony M.L., Chang D., Lee Y., Navis C.M., Hillesheim A.L., Nykaza I.R., et al. Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia. Cancer Res. 2020;80:458–470. doi: 10.1158/0008-5472.CAN-18-2932.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	Cd38	positive	1.00	1	Mouse	CD38 antigen 	CellMarker
B-cell acute lymphoblastic leukemia	DOID:0080638	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:0080638-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD38	positive	0.07	1	Human	CD38 molecule 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD38	positive	0.07	1	Human	CD38 molecule 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD38	positive	0.07	1	Human	CD38 molecule 	Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD38	negative	0.07	2	Human	CD38 molecule 	Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Hanekamp, D., Cloos, J. & Schuurhuis, G.J. Leukemic stem cells: identification and clinical application. Int J Hematol 105, 549–557 (2017). https://doi.org/10.1007/s12185-017-2221-5
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD38	positive	0.07	3	Human	CD38 molecule 	Goardon N., Marchi E., Atzberger A., Quek L., Schuh A., Soneji S., Woll P., Mead A., Alford K.A., Rout R., et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19:138–152. doi: 10.1016/j.ccr.2010.12.012.; Keyhani A., Huh Y.O., Jendiroba D., Pagliaro L., Cortez J., Pierce S., Pearlman M., Estey E., Kantarjian H., Freireich E.J. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk. Res. 2000;24:153–159. doi: 10.1016/S0145-2126(99)00147-2.; CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD38	positive	0.07	7	Human	CD38 molecule 	Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; Biolegend; van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi V, Lécrevisse Q, Lucio P, Mejstrikova E, Szczepański T, Kalina T, de Tute R, Brüggemann M, Sedek L, Cullen M, Langerak AW, Mendonça A, Macintyre E, Martin-Ayuso M, Hrusak O, Vidriales MB, Orfao A; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012 Sep;26(9):1908-75. doi: 10.1038/leu.2012.120. Epub 2012 May 3. PMID: 22552007; PMCID: PMC3437410.; Solimando, A.G.; Da Vià, M.C.; Bolli, N.; Steinbrunn, T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. Cancers 2022, 14, 3271. https://doi.org/10.3390/cancers14133271; CellMarker; Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, Popova L, Kaminiski D, Fucile CF, Albizua I, Kyu S, Chiang KY, Bradley KT, Burack R, Slifka M, Hammarlund E, Wu H, Zhao L, Walsh EE, Falsey AR, Randall TD, Cheung WC, Sanz I, Lee FE. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity. 2015 Jul 21;43(1):132-45. doi: 10.1016/j.immuni.2015.06.016. Epub 2015 Jul 14. PMID: 26187412; PMCID: PMC4680845.; BioCompare
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD44	positive	0.14	1	Human	CD44 molecule (Indian blood group) 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD44	positive	0.14	6	Human	CD44 molecule (Indian blood group) 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; CellMarker; Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Ponta H., Sherman L., Herrlich P.A. CD44: From adhesion molecules to signalling regulators. Nat. Rev. Mol. Cell Biol. 2003;4:33–45. doi: 10.1038/nrm1004.; Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006;12:1167–1174. doi: 10.1038/nm1483; Bendall L.J., Bradstock K.F., Gottlieb D.J. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia. 2000;14:1239–1246. doi: 10.1038/sj.leu.2401830.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	Cd47	positive	1.00	1	Mouse	CD47 antigen (Rh-related antigen, integrin-associated signal transducer) 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD47	positive	0.11	1	Human	CD47 molecule 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD47	positive	0.11	2	Human	CD47 molecule 	Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell138, 271–285 (2009).; Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol.24, 225–232 (2012).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD47	positive	0.11	6	Human	CD47 molecule 	Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell138, 271–285 (2009).; Majeti R., Chao M.P., Alizadeh A.A., Pang W.W., Jaiswal S., Gibbs K.D., van Rooijen N., Weissman I.L. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138:286–299. doi: 10.1016/j.cell.2009.05.045.; Sick E., Jeanne A., Schneider C., Dedieu S., Takeda K., Martiny L. CD47 update: A multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br. J. Pharmacol. 2012;167:1415–1430. doi: 10.1111/j.1476-5381.2012.02099.x.; Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, et al. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget. 2017;8:11284–301.; Chao, M. P., Weissman, I. L. & Majeti, R. The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr. Opin. Immunol.24, 225–232 (2012).; Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271–285. doi: 10.1016/j.cell.2009.05.046.
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	CD5	positive	1.00	1	Human	CD5 molecule 	Bagheri, M., Vosoughi, T., Hosseinzadeh, M. et al. Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes13, 412 (2020). https://doi.org/10.1186/s13104-020-05243-7
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD52	positive	0.50	1	Human	CD52 molecule 	Oehler, V. G. et al. CD52 expression in leukemic stem/progenitor cells. Blood116, 2743 (2010).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD52	positive	0.50	1	Human	CD52 molecule 	Oehler, V. G. et al. CD52 expression in leukemic stem/progenitor cells. Blood116, 2743 (2010).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD69	positive	0.50	2	Human	CD69 molecule 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Sachs K., Sarver A.L., Noble-Orcutt K.E., LaRue R.S., Antony M.L., Chang D., Lee Y., Navis C.M., Hillesheim A.L., Nykaza I.R., et al. Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia. Cancer Res. 2020;80:458–470. doi: 10.1158/0008-5472.CAN-18-2932.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD7	positive	0.50	1	Human	CD7 molecule 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD7	positive	0.50	1	Human	CD7 molecule 	Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD70	positive	0.33	1	Human	CD70 molecule 	Riether C., Schürch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187–198. doi: 10.1038/cdd.2014.89.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD70	positive	0.33	2	Human	CD70 molecule 	Riether C., Schürch C.M., Bührer E.D., Hinterbrandner M., Huguenin A.L., Hoepner S., Zlobec I., Pabst T., Radpour R., Ochsenbein A.F. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J. Exp. Med. 2017;214:359–380. doi: 10.1084/jem.20152008.; Riether C., Schürch C.M., Ochsenbein A.F. Regulation of hematopoietic and leukemic stem cells by the immune system. Cell Death Differ. 2015;22:187–198. doi: 10.1038/cdd.2014.89.
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	CD81	negatve	0.17	1	Human	CD81 molecule 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD81	positive	0.17	2	Human	CD81 molecule 	Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1. PMID: 27479184; PMCID: PMC5439510.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CD81	negative	0.17	3	Human	CD81 molecule 	Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.; BioCompare; Milteny Biotec
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD82	positive	1.00	1	Human	CD82 molecule 	de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell34, 674–689.e8 (2018).
B-cell acute lymphoblastic leukemia	DOID:0080638	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:0080638-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD9	positive	0.10	1	Human	CD9 molecule 	CellMarker
acute lymphoblastic leukemia	DOID:9952	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9952-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD9	positive	0.10	1	Human	CD9 molecule 	Brosseau C., Colas L., Magnan A., Brouard S. CD9 tetraspanin: A new pathway for the regulation of inflammation? Front. Immunol. 2018;9:2316. doi: 10.3389/fimmu.2018.02316.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD9	positive	0.10	4	Human	CD9 molecule 	Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Touzet, L. et al. CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells. Cancer. Med.8, 1279–1288 (2019).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD9	positive	0.10	4	Human	CD9 molecule 	Touzet, L. et al. CD9 in acute myeloid leukemia: prognostic role and usefulness to target leukemic stem cells. Cancer. Med.8, 1279–1288 (2019).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Paprocka M., Bielawska-Pohl A., Rossowska J., Krawczenko A., Duś D., Kiełbiński M., Haus O., Podolak-Dawidziak M., Kuliczkowski K. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients. Eur. J. Haematol. 2017;99:415–422. doi: 10.1111/ejh.12938.; Touzet L., Dumezy F., Roumier C., Berthon C., Bories C., Quesnel B., Preudhomme C., Boyer T. CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells. Cancer Med. 2019;8:1279–1288. doi: 10.1002/cam4.2007.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD93	positive	0.10	4	Human	CD93 molecule 	Greenlee-Wacker, M. C., Galvan, M. D. & Bohlson, S. S. CD93: recent advances and implications in disease. Curr. Drug Targets13, 411–420 (2012).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.; Kinstrie, R. et al. CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia. Blood126, 49–49 (2015).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD93	positive	0.10	6	Human	CD93 molecule 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Greenlee-Wacker, M. C., Galvan, M. D. & Bohlson, S. S. CD93: recent advances and implications in disease. Curr. Drug Targets13, 411–420 (2012).; Kinstrie, R. et al. CD93 is a novel biomarker of leukemia stem cells in chronic myeloid leukemia. Blood126, 49–49 (2015).; Bohlson S., Greenlee M., Sullivan S. CD93 and Related Family Members: Their Role in Innate Immunity. Curr. Drug Targets. 2008;9:130–138. doi: 10.2174/138945008783502421.; Iwasaki M., Liedtke M., Gentles A.J., Cleary M.L. CD93 marks a non-quiescent human leukemia stem cell population and is required for development of MLL-rearranged acute myeloid leukemia. Cell Stem Cell. 2015;17:412–421.; Sumide K., Matsuoka Y., Kawamura H., Nakatsuka R., Fujioka T., Asano H., Takihara Y., Sonoda Y. A revised road map for the commitment of human cord blood CD34-negative hematopoietic stem cells. Nat. Commun. 2018;9:2202. doi: 10.1038/s41467-018-04441-z.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD96	positive	0.14	1	Human	CD96 molecule 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD96	positive	0.14	6	Human	CD96 molecule 	Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Hosen, N. et al. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc. Natl Acad. Sci. USA104, 11008–11013 (2007).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Al-Fatlawi H., Musa R. Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy. Iraqi J. Hematol. 2016;5:161–166. doi: 10.4103/2072-8069.198119.; Georgiev H., Ravens I., Papadogianni G., Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. Front. Immunol. 2018;9:1072. doi: 10.3389/fimmu.2018.01072.; Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	CD99	positive	0.33	3	Human	CD99 molecule (Xg blood group) 	Chung SS, Tavakkoli M, Klimek VM, Park CY. CD99 is a therapeutic target on disease stem cells in acute myeloid leukemia and the myelodysplastic syndromes. Blood. 2014;124:3760.; Chung, S. S. et al. CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Sci. Transl. Med.9, eaaj2025 (2017).; Celik, H. et al. Discovery of first-in-class small molecule CD99 inhibitors for targeted therapy of Ewing sarcoma. Cancer Res. 77 (13 Suppl.), Abstract nr 1933 (2017).
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	CIITA	positive	0.50	2	Human	class II major histocompatibility complex transactivator 	Scharer, C.D., Barwick, B.G., Guo, M. et al. Plasma cell differentiation is controlled by multiple cell division-coupled epigenetic programs. Nat Commun9, 1698 (2018). https://doi.org/10.1038/s41467-018-04125-8; Minnich, M., Tagoh, H., Bönelt, P. et al. Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation. Nat Immunol17, 331–343 (2016). https://doi.org/10.1038/ni.3349
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	DKK1	positive	1.00	1	Human	dickkopf WNT signaling pathway inhibitor 1 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	DPP4	negative	0.20	1	Human	dipeptidyl peptidase 4 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	DPP4	positive	0.20	1	Human	dipeptidyl peptidase 4 	Valent, P. et al. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur. J. Clin. Invest.44, 1239–1245 (2014).
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	DPP4	positive	0.20	3	Human	dipeptidyl peptidase 4 	Valent, P. et al. DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. Eur. J. Clin. Invest.44, 1239–1245 (2014).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	EDNRB	positive	1.00	1	Human	endothelin receptor type B 	CellMarker
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	FCER2	positive	1.00	1	Human	Fc fragment of IgE receptor II 	Bagheri, M., Vosoughi, T., Hosseinzadeh, M. et al. Evaluation of immunophenotypic markers and clinico-hematological profile in chronic lymphocytic leukemia: implications for prognosis. BMC Res Notes13, 412 (2020). https://doi.org/10.1186/s13104-020-05243-7
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	FCGR2A	positive	0.33	1	Human	Fc fragment of IgG receptor IIa 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	FCGR2A	positive	0.33	2	Human	Fc fragment of IgG receptor IIa 	Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci.Transl. Med.2, 17ra9 (2010).
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	FCGR2B	positive	1.00	1	Human	Fc fragment of IgG receptor IIb 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	FCGR2C	positive	1.00	1	Human	Fc fragment of IgG receptor IIc (gene/pseudogene) 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	FCRL5	positive	1.00	1	Human	Fc receptor like 5 	BioCompare
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	FRZB	positive	1.00	1	Human	frizzled related protein 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	GLI1	positive	1.00	1	Human	GLI family zinc finger 1 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	GLI2	positive	1.00	1	Human	GLI family zinc finger 2 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	HAVCR2	positive	0.20	1	Human	hepatitis A virus cellular receptor 2 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	HAVCR2	positive	0.20	4	Human	hepatitis A virus cellular receptor 2 	CellMarker; Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Kikushige, Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell7, 708–717 (2010).; Haubner S., Perna F., Köhnke T., Schmidt C., Berman S., Augsberger C., Schnorfeil F.M., Krupka C., Lichtenegger F.S., Liu X., et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64–74. doi: 10.1038/s41375-018-0180-3.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	HMMR	positive	1.00	1	Human	hyaluronan mediated motility receptor 	Abcam
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	ITGAE	positive	1.00	1	Human	integrin subunit alpha E 	de Boer, B. et al. Prospective isolation and characterization of genetically and functionally distinct AML subclones. Cancer Cell34, 674–689.e8 (2018).
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	ICAM1	positive	0.50	2	Human	intercellular adhesion molecule 1 	BioCompare; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	IFI27	positive	1.00	1	Human	interferon alpha inducible protein 27 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	IRF4	positive	0.50	2	Human	interferon regulatory factor 4 	Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T, Ludwig T, Rajewsky K, Dalla-Favera R. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006 Jul;7(7):773-82. doi: 10.1038/ni1357. Epub 2006 Jun 11. PMID: 16767092.; Shaffer, A., Emre, N., Lamy, L. et al. IRF4 addiction in multiple myeloma. Nature454, 226–231 (2008). https://doi.org/10.1038/nature07064
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	IRF8	positive	1.00	1	Human	interferon regulatory factor 8 	Wang H, Lee CH, Qi C, Tailor P, Feng J, Abbasi S, Atsumi T, Morse HC 3rd. IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood. 2008 Nov 15;112(10):4028-38. doi: 10.1182/blood-2008-01-129049. Epub 2008 Sep 17. PMID: 18799728; PMCID: PMC2581985.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL1RAP	positive	0.08	1	Human	interleukin 1 receptor accessory protein 	CellMarker; CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL1RAP	positive	0.08	4	Human	interleukin 1 receptor accessory protein 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.; Jaras, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl Acad. Sci. USA107, 16280–16285 (2010).; Askmyr, M. et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood121, 3709–3713 (2013).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL1RAP	positive	0.08	6	Human	interleukin 1 receptor accessory protein 	Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci. 2015;112:10786–91.; Askmyr M, Ågerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709–13.; Askmyr, M. et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood121, 3709–3713 (2013).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Jaras, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl Acad. Sci. USA107, 16280–16285 (2010).; Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 2012;120:1290–8.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL2RA	positive	0.08	1	Human	interleukin 2 receptor subunit alpha 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL2RA	positive	0.08	5	Human	interleukin 2 receptor subunit alpha 	Kageyama Y., Miwa H., Arakawa R., Tawara I., Ohishi K., Masuya M., Nakase K., Katayama N. Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML. PLoS ONE. 2018;13:e0209295. doi: 10.1371/journal.pone.0209295.; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.; Sadovnik, I. et al. Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML. Clin. Cancer Res.22, 2051–2061 (2016).; Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci.Transl. Med.2, 17ra9 (2010).
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL2RA	positive	0.08	6	Human	interleukin 2 receptor subunit alpha 	Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, Takagi S, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells yoriko. Sci Transl Med. 2010;2:179.; Sadovnik, I. et al. Identification of CD25 as STAT5-dependent growth regulator of leukemic stem cells in Ph+ CML. Clin. Cancer Res.22, 2051–2061 (2016).; Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci.Transl. Med.2, 17ra9 (2010).; Kageyama Y., Miwa H., Arakawa R., Tawara I., Ohishi K., Masuya M., Nakase K., Katayama N. Expression of CD25 fluctuates in the leukemia-initiating cell population of CD25-positive AML. PLoS ONE. 2018;13:e0209295. doi: 10.1371/journal.pone.0209295.; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL3RA	positive	0.07	1	Human	interleukin 3 receptor subunit alpha 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL3RA	positive	0.07	3	Human	interleukin 3 receptor subunit alpha 	Ito K, Ito K. Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia. Cancers (Basel). 2021 Nov 20;13(22):5822. doi: 10.3390/cancers13225822. PMID: 34830976; PMCID: PMC8616035.; Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	IL3RA	positive	0.07	10	Human	interleukin 3 receptor subunit alpha 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Sadovnik, I. et al. Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: potential diagnostic value and functional implications. Exp. Hematol.51, 17–24 (2017).; Ding Y, Gao H, Zhang Q. The biomarkers of leukemia stem cells in acute myeloid leukemia. Stem Cell Investig. 2017 Mar 2;4:19. doi: 10.21037/sci.2017.02.10. PMID: 28447034; PMCID: PMC5388677.; Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Haubner S., Perna F., Köhnke T., Schmidt C., Berman S., Augsberger C., Schnorfeil F.M., Krupka C., Lichtenegger F.S., Liu X., et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33:64–74. doi: 10.1038/s41375-018-0180-3.; Guthridge M.A., Stomski F.C., Thomas D., Woodcock J.M., Bagley C.J., Berndt M.C., Lopez A.F. Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells. 1998;16:301–313. doi: 10.1002/stem.160301.; Al-Mawali A., Pinto A.D., Al-Zadjali S. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection. Acta Haematol. 2017;138:175–181. doi: 10.1159/000480448.; Bras A.E., de Haas V., van Stigt A., Jongen-Lavrencic M., Beverloo H.B., te Marvelde J.G., Zwaan C.M., van Dongen J.J.M., Leusen J.H.W., van der Velden V.H.J. CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping. Cytom. Part B Clin. Cytom. 2019;96:134–142. doi: 10.1002/cyto.b.21745.; Wells S.J., Bray R.A., Stempora L.L., Farhi D.C. CD117/CD34 expression in leukemic blasts. Am. J. Clin. Pathol. 1996;106:192–195. doi: 10.1093/ajcp/106.2.192.; CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	IL6R	positive	1.00	1	Human	interleukin 6 receptor 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	Kit	positive	1.00	1	Mouse	KIT proto-oncogene receptor tyrosine kinase 	CellMarker
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	KIT	positive	0.11	1	Human	KIT proto-oncogene, receptor tyrosine kinase 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	KIT	positive	0.11	3	Human	KIT proto-oncogene, receptor tyrosine kinase 	Milteny Biotec; BioCompare; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	KIT	positive	0.11	5	Human	KIT proto-oncogene, receptor tyrosine kinase 	Sperling C., Schwartz S., Büchner T., Thiel E., Ludwig W.D. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica. 1997;82:617–621.; Wells S.J., Bray R.A., Stempora L.L., Farhi D.C. CD117/CD34 expression in leukemic blasts. Am. J. Clin. Pathol. 1996;106:192–195. doi: 10.1093/ajcp/106.2.192.; Geissler E.N., Liao M., Brook J.D., Martin F.H., Zsebo K.M., Housman D.E., Galli S.J. Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. Somat Cell Mol. Genet. 1991;17:207–214. doi: 10.1007/BF01232978.; CellMarker; Quek L., Otto G.W., Garnett C., Lhermitte L., Karamitros D., Stoilova B., Lau I.J., Doondeea J., Usukhbayar B., Kennedy A., et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage. J. Exp. Med. 2016;213:1513–1535. doi: 10.1084/jem.20151775.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	Ly6a	positive	1.00	1	Mouse	lymphocyte antigen 6 complex, locus A 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	MZB1	positive	1.00	1	Human	marginal zone B and B1 cell specific protein 	Cohen, Y.C., Zada, M., Wang, SY. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 27, 491–503 (2021). https://doi.org/10.1038/s41591-021-01232-w
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	MME	negative	0.33	1	Human	membrane metalloendopeptidase 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	MME	positive	0.33	2	Human	membrane metalloendopeptidase 	Morgan D, Tergaonkar V. Unraveling B cell trajectories at single cell resolution. Trends Immunol. 2022 Mar;43(3):210-229. doi: 10.1016/j.it.2022.01.003. Epub 2022 Jan 25. PMID: 35090788.; Liu, R., Gao, Q., Foltz, S.M. et al. Co-evolution of tumor and immune cells during progression of multiple myeloma. Nat Commun 12, 2559 (2021). https://doi.org/10.1038/s41467-021-22804-x
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	MS4A1	negative	0.20	1	Human	membrane spanning 4-domains A1 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	MS4A1	negative	0.20	2	Human	membrane spanning 4-domains A1 	Solimando, A.G.; Da Vià, M.C.; Bolli, N.; Steinbrunn, T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. Cancers 2022, 14, 3271. https://doi.org/10.3390/cancers14133271; Biolegend
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	MS4A1	positive	0.20	2	Human	membrane spanning 4-domains A1 	Biolegend; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	MUC1	positive	1.00	1	Human	mucin 1, cell surface associated 	ThermoFisher
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	MSI2	positive	1.00	1	Human	musashi RNA binding protein 2 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	NCAM1	positive	0.11	1	Human	neural cell adhesion molecule 1 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	NCAM1	positive	0.11	3	Human	neural cell adhesion molecule 1 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.; Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439–46.; Sasca D., Szybinski J., Schüler A., Shah V., Heidelberger J., Haehnel P.S., Dolnik A., Kriege O., Fehr E.M., Gebhardt W.H., et al. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood. 2019;133:2305–2319. doi: 10.1182/blood-2018-12-889725.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	NCAM1	positive	0.11	5	Human	neural cell adhesion molecule 1 	CellMarker; Solimando, A.G.; Da Vià, M.C.; Bolli, N.; Steinbrunn, T. The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring “Multiple Myelomas”. Cancers 2022, 14, 3271. https://doi.org/10.3390/cancers14133271; Milteny Biotec; BioCompare; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	PAX5	positive	1.00	1	Human	paired box 5 	Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1. PMID: 27479184; PMCID: PMC5439510.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	PRDM1	positive	1.00	1	Human	PR/SET domain 1 	Minnich, M., Tagoh, H., Bönelt, P. et al. Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation. Nat Immunol 17, 331–343 (2016). https://doi.org/10.1038/ni.3349
B-cell acute lymphoblastic leukemia	DOID:0080638	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:0080638-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	PROM1	positive	1.00	1	Human	prominin 1 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	PTPRC	negative	0.17	3	Human	protein tyrosine phosphatase receptor type C 	Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016 Dec;101(12):1451-1459. doi: 10.3324/haematol.2015.138826. Epub 2016 Nov 10. PMID: 27903712; PMCID: PMC5479618.; Milteny Biotec; Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. PMID: 26100534.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	PTPRC	positive	0.17	3	Human	protein tyrosine phosphatase receptor type C 	BioCompare; Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF. Differentiation stage of myeloma plasma cells: biological and clinical significance. Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1. PMID: 27479184; PMCID: PMC5439510.; Muz, B., de la Puente, P., Azab, F. et al. Hypoxia promotes stem cell-like phenotype in multiple myeloma cells. Blood Cancer Journal4, e262 (2014). https://doi.org/10.1038/bcj.2014.82
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	ROR1	positive	1.00	1	Human	receptor tyrosine kinase like orphan receptor 1 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	ROBO4	negative	0.50	1	Human	roundabout guidance receptor 4 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	ROBO4	positive	0.50	1	Human	roundabout guidance receptor 4 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
chronic lymphocytic leukemia	DOID:1040	CD5+ B cell	CD5+ B cell (Hs)	DOID:1040-CL:0000236	A cell which express B-phenotype and the CD5 antigen which is usually present on the surface of normal T cells	SPN	positive	1.00	1	Human	sialophorin 	Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17. PMID: 29024461; PMCID: PMC5817234.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	STAT5B	positive	0.50	2	Human	signal transducer and activator of transcription 5B 	Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, Wijnands E, Gimeno R, Vyth-Dreese FA, Blom B, Spits H. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat Immunol. 2005 Mar;6(3):303-13. doi: 10.1038/ni1172. Epub 2005 Feb 13. PMID: 15711548.; Pelham SJ, Caldirola MS, Avery DT, Mackie J, Rao G, Gothe F, Peters TJ, Guerin A, Neumann D, Vokurkova D, Hwa V, Zhang W, Lyu SC, Chang I, Manohar M, Nadeau KC, Gaillard MI, Bezrodnik L, Iotova V, Zwirner NW, Gutierrez M, Al-Herz W, Goodnow CC, Vargas-Hernández A, Forbes Satter LR, Hambleton S, Deenick EK, Ma CS, Tangye SG. STAT5B restrains human B-cell differentiation to maintain humoral immune homeostasis. J Allergy Clin Immunol. 2022 Oct;150(4):931-946. doi: 10.1016/j.jaci.2022.04.011. Epub 2022 Apr 22. PMID: 35469842.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	SLAMF7	positive	1.00	1	Human	SLAM family member 7 	Kikuchi J, Hori M, Iha H, Toyama-Sorimachi N, Hagiwara S, Kuroda Y, Koyama D, Izumi T, Yasui H, Suzuki A, Furukawa Y. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7. Leukemia. 2020 Jan;34(1):180-195. doi: 10.1038/s41375-019-0525-6. Epub 2019 Jul 29. PMID: 31358854.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	SDC1	positive	0.17	6	Human	syndecan 1 	CellMarker; Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K. The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica. 2016 Dec;101(12):1451-1459. doi: 10.3324/haematol.2015.138826. Epub 2016 Nov 10. PMID: 27903712; PMCID: PMC5479618.; BioCompare; Milteny Biotec; Cohen, Y.C., Zada, M., Wang, SY. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 27, 491–503 (2021). https://doi.org/10.1038/s41591-021-01232-w; Halliley JL, Tipton CM, Liesveld J, Rosenberg AF, Darce J, Gregoretti IV, Popova L, Kaminiski D, Fucile CF, Albizua I, Kyu S, Chiang KY, Bradley KT, Burack R, Slifka M, Hammarlund E, Wu H, Zhao L, Walsh EE, Falsey AR, Randall TD, Cheung WC, Sanz I, Lee FE. Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity. 2015 Jul 21;43(1):132-45. doi: 10.1016/j.immuni.2015.06.016. Epub 2015 Jul 14. PMID: 26187412; PMCID: PMC4680845.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	TEK	positive	1.00	1	Human	TEK receptor tyrosine kinase 	CellMarker
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	THY1	negative	0.12	1	Human	Thy-1 cell surface antigen 	Herrmann H., Sadovnik I., Eisenwort G., Thomas R., Blatt K., Herndlhofer S., Willmann M., Stefanzl G., Baumgartner S., Greiner G., et al. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38− stem and progenitor cells in AML and CML. Blood Adv. 2020;4:5118–5132. doi: 10.1182/bloodadvances.2020001742.
leukemia	DOID:1240	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:1240-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	THY1	positive	0.12	1	Human	Thy-1 cell surface antigen 	CellMarker
chronic myeloid leukemia	DOID:8552	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:8552-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	THY1	positive	0.12	1	Human	Thy-1 cell surface antigen 	Brendel C., Mohr B., Schimmelpfennig C., Muller J., Bornhauser M., Schmidt M., Ritter M., Ehninger G., Neubauer A. Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias. Leukemia. 1999;13:1770–1775. doi: 10.1038/sj.leu.2401543.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	THY1	positive	0.12	5	Human	Thy-1 cell surface antigen 	CellMarker; Buccisano F., Rossi F.M., Venditti A., Del Poeta G., Cox M.C., Abbruzzese E., Rupolo M., Berretta M., Degan M., Russo S., et al. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br. J. Haematol. 2004;125:203–212.; Brendel C., Mohr B., Schimmelpfennig C., Muller J., Bornhauser M., Schmidt M., Ritter M., Ehninger G., Neubauer A. Detection of cytogenetic aberrations both in CD90 (Thy-1)-positive and (Thy-1)-negative stem cell (CD34) subfractions of patients with acute and chronic myeloid leukemias. Leukemia. 1999;13:1770–1775. doi: 10.1038/sj.leu.2401543.; Craig W., Kay R., Cutler R.L., Lansdorp P.M. Expression of Thy-1 on human hematopoietic progenitor cells. J. Exp. Med. 1993;177:1331–1342. doi: 10.1084/jem.177.5.1331.; Blair A., Hogge D.E., Ailles L.E., Lansdorp P.M., Sutherland H.J. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104–3112. doi: 10.1182/blood.V89.9.3104.
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	TNFRSF17	positive	0.25	4	Human	TNF receptor superfamily member 17 	Abcam; Cohen, Y.C., Zada, M., Wang, SY. et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med 27, 491–503 (2021). https://doi.org/10.1038/s41591-021-01232-w; O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004 Jan 5;199(1):91-8. doi: 10.1084/jem.20031330. PMID: 14707116; PMCID: PMC1887725.; Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. PMID: 30147690; PMCID: PMC6095983.
acute myeloid leukemia	DOID:9119	leukemia stem cell	leukemia stem cell (Hs, Mm)	DOID:9119-CL:0000037	A normal stem or progenitor cell undergoes a mutation, giving rise to an entity that is functionally defined as a leukemic stem cell	TFRC	positive	1.00	1	Human	transferrin receptor 	CellMarker
multiple myeloma	DOID:9538	myeloma plasma cell	myeloma plasma cell (Hs)	DOID:9538-CL:0000786	Multiple myeloma cells are abnormal plasma cells (a type of white blood cell) that build up in the bone marrow and form tumors in many bones of the body.	XBP1	positive	0.50	2	Human	X-box binding protein 1 	Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity. 2004 Jul;21(1):81-93. doi: 10.1016/j.immuni.2004.06.010. PMID: 15345222.; Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, Vaxman I, Pasvolsky O, Ballan M, Tadmor T, Nemets A, Jarchowcky-Dolberg O, Shvetz O, Laiba M, Shpilberg O, Dally N, Avivi I, Weiner A, Amit I. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021 Mar;27(3):491-503. doi: 10.1038/s41591-021-01232-w. Epub 2021 Feb 22. PMID: 33619369; PMCID: PMC7612793.
